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What is known about this subject?
 Previous studies have been contradictory with both negative and positive associations between smoking and
the incidence of melanoma reported.
 Previous studies have either been limited by publication bias due to selective reporting or underpowered.
What does this study add?
 Our large study identified an inverse association between smoking status and melanoma incidence.
 Whilst smoking status was negatively associated with overall disease survival, no significant association was
noted in melanoma-specific survival.
 Socioeconomic status remains closely associated with melanoma. Whilst higher socioeconomic populations




Previous studies have identified an inverse association between melanoma and smoking; however 
data from population based studies are scarce.
Objective
To determine the association between smoking and socioeconomic status on the risk of 
development of melanoma. Furthermore, we sought to determine the implications of smoking and 
socioeconomic status on survival.
Methods
We conducted a population-based case-control study. Cases were identified from the Welsh 
Cancer Intelligence and Surveillance Unit (WCISU) during 2000-2015 and controls identified 
from the general population. Smoking and socioeconomic status were obtained from data linkage 
with other national databases. The association of smoking status and socioeconomic status on the 
incidence of melanoma were assessed using binary logistic regression. Multivariate survival 
analysis were performed on a melanoma cohort using Cox proportional hazard model using 
survival as the outcome.
Results
During 2000-2015, 9,636 patients developed melanoma. Smoking data were obtained for 7,124 
(73.9%) of these patients. 26,408 controls were identified from the general population. Smoking 
was inversely associated with melanoma incidence (Odds Ratio (OR) 0.70 95% CI 0.65 -0.76). 
Smoking was associated with an increased overall mortality (Hazard Ratio (HR) 1.30 95% CI 
1.09-1.55), but not associated with melanoma specific mortality. Patients with higher 
socioeconomic status had an increased association with melanoma incidence (OR 1.58 95% CI 
1.44-1.73). Higher socioeconomic status was associated with an increased chance of both overall 
(HR 0.67 95% CI 0.56-0.81) and disease specific survival (HR 0.69 95% CI 0.53-0.90).
Conclusion
Our study has demonstrated that smoking appeared to be associated with reduced incidence of 
melanoma. Whilst smoking increases overall mortality, no association was observed with 
melanoma-specific mortality. Further work is required to determine if there is a biological 
mechanism underlying this relationship or an alternative explanation, such as survival bias. 
Keywords:
Melanoma; Smoking; socioeconomic status; data-linkage; registry.
1. Introduction
Whilst there is a wealth of knowledge on the association of melanoma with risk factors such as 
ultraviolet light exposure, skin type and genetics1, the relationship between tobacco smoke and 
melanoma is less clear. Tobacco smoke is a type 1 carcinogen, associated with 18 types of cancer2. 
Song et al3 reported a moderate inverse association between melanoma and smoking in a meta-
analysis of two cohort studies. This association was observed in both ex-smokers and current 
smokers in men, but not women. A larger meta-analysis, including 23 studies, reported a similar 
inverse association4. Both papers reported significant limitations, notably publication bias due to 
selective reporting in the published studies. Furthermore, confounding variables were not included 
in the analysis.
A recent, prospective cohort study has further explored the association. After adjusting for 
potential confounding factors, no association was observed between current smoking and 
melanoma (OR 1.01 95% CI 0.64 -1.61)5. Whilst the study addressed the aforementioned 
limitations by adjusting for confounding factors, the study was significantly underpowered;  only a 
small proportion of the cohort developed melanoma and the average follow up duration was short 
(3.5 years).
The relationship between socioeconomic status and melanoma, on the other hand, is well 
established in the literature, with research dating back to the 1980s6,7. Those in higher income or 
higher educational groups are at an increased risk of developing melanoma, attributed to greater 
exposure to lifestyle factors, such as sun holidays and tanning bed use8. However, once diagnosed, 
those with a lower socioeconomic status have a worse prognosis, a finding seen across multiple 
jurisdictions with different health care systems8. Understanding and addressing this worsened 
prognosis is therefore a clear public health priority9-11.
In this paper we describe the largest study investigating the association of smoking and melanoma 
published to date. We have used the power of routinely collected data to overcome limitations of 
previous studies and investigate the prognostic implications of smoking in this patient cohort. 
Furthermore, we sought to investigate the association of socioeconomic status on the incidence 
and survival of melanoma.
2. Methods
The described study has been reported in accordance with the Reporting of studies Conducted 
using Observational Routinely-collected health Data (RECORD) statement 12. 
The study was conducted in two stages. In stage one; a case control study was performed to assess 
the relationship between smoking and the development of melanoma. In stage two, a cohort study 
was conducted to determine the association between smoking and survival within the melanoma 
cohort (Figure 1).
2.1 Overview of methods
Analysis of primary and secondary care National Health Service (NHS) data and national 
administrative data for 2000-2015 in Wales, UK (population 3.1 million) were performed. In 
instances where relevant data were unavailable from a single source, multiple datasets were 
linked. Data were retrieved from six national databases (Table 1). In Wales, population level de-
identified person-based health and socio-economic administrative datasets are collated and linked 
within the Secure Anonymised Information Linkage (SAIL) Databank13-15. Robust policies, 
structures and controls are in place to protect privacy through a reliable matching and 
anonymization process, achieved in conjunction with the NHS Wales Informatics Service (NWIS) 
using a split file multiple encryption approach described in detail in previous published work14.
Table 1 - List of databases used and their description
2.2 Cases
In Wales, all patients with a diagnosis of melanoma are recorded in the Welsh Cancer Intelligence 
and Surveillance Unit (WCISU) register. Cases were identified from WCISU using International 
Classification of Disease 10 (ICD-10) codes C43.0-C43.9 and morphology codes according to the 
International Classification of Diseases for Oncology (ICDO-3) 8720-879016. Patients with 
melanoma in situ were not included in the study as either cases or controls. Demographic 
information was assessed at the diagnostic date. Melanoma specific variables (tumour location, 
stage and morphology) were assessed at the diagnostic date. 
2.3 Controls
Four sets of general population controls were randomly selected from the Welsh Demographic 
Service Dataset (WDSD). Controls were not matched to cases. Both cases and controls needed to 
be alive and resident in Wales on the date of melanoma diagnosis. To increase the power of the 
study we aimed to have four controls for every case17.
2.4 Smoking status
Self-reported smoking status, for cases and controls were obtained from the Welsh Longitudinal 
General Practice (WLGP) data, as recorded during patients’ consultations with their General 
Practitioner in primary care, using Read codes that have been previously validated18 (Appendix 1). 
Patients were defined as either a non-smoker (for lifelong non-smokers), ex-smoker (for those that 
had previously smoked) or current smokers. The smoking assessment window extended from the 
melanoma diagnosis date to six months prior. Where serial assessments were available, the 
smoking record most recent to the diagnosis was selected. Where “non-smoker” was recorded, the 
WLGP dataset was explored to establish whether the individual had previously been classified as a 
smoker. In such circumstances, the individual was classed as an ex-smoker.
2.5 Socioeconomic status
Socioeconomic status was measured using the Welsh Index of Multiple Deprivation (WIMD) 
version 2001, a measure based on the Index of Multiple Deprivation and used as the official 
measure of socioeconomic status for the Welsh Government19. Individual scores are based upon a 
person’s postal address. Wales is divided into 1,896 Lower-Layer Super-Output Areas (LSOAs) 
following the 2001 Census, each consisting of approximately 1600 people. The WIMD scores for 
each LSOA are calculated from weighted scores from eight domains of socioeconomic status 
(income, employment, health, education, access to services, community safety, physical 
environment and housing socioeconomic status). Each LSOA in Wales has been ranked according 
to its WIMD score and grouped into quintiles, with quintile 5 being the highest socioeconomic 
status and 1 being the lowest.
2.6 Mortality data
Data relating to mortality, including cause of death, were obtained on the melanoma cohort from 
the Annual District Death Extract (ADDE) dataset, which contains the diagnostic codes listed on 
patient’s death certificates, held within the SAIL Databank.
2.7 Charlson Co-morbidity Index
The Charlson co-morbidity index is a widely used measure of co-morbidity. An overall score is 
calculated from a list of conditions, each of which has been allocated a weight of between one and 
six based upon its adjusted relative risk of one-year mortality20.
2.8 Ethical approval
Study approval was granted by the SAIL Databank independent Information Governance Review 
Panel (IGRP) (project 0593). Data held within the SAIL Databank are made available to 
researchers in an anonymised format and are therefore not subject to data protection legislation. 
SAIL follows all relevant legislative and regulatory frameworks in using population data for 
research.
2.9 Statistical analysis
Case – Control (Stage 1)
Descriptive statistics were used to characterise the melanoma cases and controls by smoking status 
and stage at diagnosis (cases only). An unconditional binary logistic regression model was used to 
calculate odds ratios with 95% confidence intervals for the association with melanoma. Sex, 
socioeconomic status and age at the time of diagnosis (as a continuous variable) were incorporated 
into the statistical model as confounders.
Cohort Study (Melanoma patients only) (Stage 2)
In this stage of the study on those with a  diagnosis of melanoma were included (Figure1). Overall 
survival was calculated as the time from melanoma diagnosis to the time of death (outcome) or the 
end of the study (December 2018). Melanoma-specific survival was calculated as the time from 
melanoma diagnosis to the date of death from melanoma, or the end of the study for patients still 
alive (December 2018). Cases with missing variables were excluded from this aspect of the study.
Kaplan-Meier curves were generated for smoking status and socioeconomic status, with curves 
compared using the log-rank test. A Cox hazard proportional regression model was used to 
determine the association between smoking and mortality in the melanoma cohort. Sex, 
socioeconomic status, melanoma stage at diagnosis and age at diagnosis as a continuous variable 
were incorporated into the model as confounders. Both overall survival (deaths from any cause) 
and melanoma-specific survival (defined on their death registration held within ADDE) were 
analysed in the melanoma cohort. All data were analysed using IBM SPSS Statistics for Windows 
(IBM Corp. Released 2017. Version 25.0. Armonk, NY: IBM Corp). Statistical significance was 
assumed with a p < 0.05.
Results 
Between 2000 and 2015, 9,636 patients were diagnosed with melanoma in Wales.
Stage 1 Case-Control study
Patient demographics and clinical characteristics of the cases and controls are outlined in Table 2. 
Data relating to smoking status were available for 7,124 (73.9%) of the melanoma cohort; 1,460 
current smokers (20.6%), 3,065 (43.2%) ex-smokers and 2,599 (36.6%) non-smokers.
Smoking
After adjusting for sex, age and socioeconomic status, current smokers had 30% reduced odds for 
developing melanoma compared to non-smokers, (OR 0.70 95% CI 0.65-0.76) (Table 3). There 
was no association between being an ex-smoker or non-smokers and melanoma (OR 1.05 95% CI 
0.98-1.12).
Socioeconomic status 
We observed an inverse relationship between socioeconomic status and melanoma, whereby 
patients from higher socioeconomic WIMD quintiles were more likely to develop melanoma. 
Those in the highest socioeconomic quintile (WIMD 5) were 1.58 times more likely to develop 
melanoma as opposed to the lowest (HR 1.58 95% CI 1.44-1.73) (Table 3).
Table 3 Univariable logistic regression assessing risk factors for melanoma
Stage 2 Survival analysis of the melanoma cohort 
Table 4 displays the demographics of the melanoma cohort.
Demographic data
Table 4 displays the demographics of the melanoma cohort. The median age at diagnosis was 
higher in non-smokers (66.7y) and ex smokers (64.5y) than in current smokers (62.4y). 
Socioeconomic status had significant variation amongst groups, with the current and ex-smokers 
being more likely to have lower socioeconomic status WIMD quintiles. Stage at diagnosis was not 
significantly different between smoking groups or socioeconomic status. No differences between 
the mean Charlson co-morbidity scores were noted between the smoking groups or between 
WIMD quintiles (Table 4). 
Mortality
A total of 3,103 (32.2%) patients with melanoma died during the study period. Of these, 1,688 
(54.4%) died from melanoma (melanoma listed as the primary cause of death on their death 
certificate) and 1,415 (45.6%) deaths were unrelated to melanoma. For patients who died from any 
cause, median time to death was 2.36 years. For patients who died of melanoma, median time to 
death was 1.73 years.
Univariate survival analysis
Median follow up duration of the entire cohort was 5.22 years (range: 0 – 18 years). Overall 
survival rates were different across the three smoking status groups, with ex-smokers having lower 
survival that current or non-smokers (p<0.00). In contrast, no difference was observed across the 
three smoking status groups for disease specific mortality (p=0.88). Overall and melanoma-
specific survival rates by smoking status and socioeconomic status are shown in the 
supplementary figures. Figures 2 and 3 shows the overall and disease specific survival curves by 
smoking status.
Overall and disease specific survival rates differed significantly across the WIMD quintiles (Table 
6 and 7).Figures 4 and 5 show the overall and disease survival curves by socioeconomic status.
Figure 2 Overall Survival by smoking status
Figure 3 Disease specific survival rates by smoking status
Figure 4 Overall Survival by socioeconomic status
Figure 5 Disease specific survival by socioeconomic status 
Multivariable survival analysis
After adjusting for the aforementioned factors, current smokers had an increased overall risk of 
death as compared to non-smokers (HR 1.30 95% CI 1.09-1.55). There was no association 
between current smoking and melanoma-specific mortality. Increased odds of survival was noted 
in the highest socioeconomic WIMD quintile (quintile 5), compared to the lowest (quintile 1) (HR 
0.67 95% CI 0.54-0.79). A similar trend was observed with disease specific mortality (HR 0.69 
95% CI 0.56-0.81).
Males had an increased risk of overall and melanoma-specific death compared to females (Overall 
HR 1.28 95% CI 1.13-1.46) Disease specific (HR 1.35 95% CI 1.12-1.62). Tumour location was 
an important predictor of survival. For overall survival, tumours located on the upper limb were 
associated with increased survival compared to those on the trunk (HR 0.73 95% CI 0.61-0.88), 
with no association between tumours on the head and neck and lower limbs however. With regards 
to melanoma-specific mortality, tumours located on the trunk were associated with an increased 
risk of mortality when compared to those in other locations. Age was associated with a small 
increased risk of overall and melanoma-specific mortality (Overall HR 1.06 95% CI 1.05-1.06 p < 
0.00; disease specific HR 1.02 95% CI 1.01-1.03 p < 0.00). Melanoma morphology was not 
associated with overall survival, however melanoma-specific mortality was increased in those with 
nodular melanoma (HR 1.23 95% CI 0.98-1.54) whereas those with lentigo maligna melanoma 
had improved survival (HR 0.43 95% CI 0.21-0.89). The Charlson co-morbidity index was not 
association with overall (HR 1.01 95% CI 1.00 -1.017) or melanoma-specific survival (HR 1.00 
95% CI 0.99 -1.02).
Table 5 Cox model for overall and disease specific survival
Discussion
We found that smokers were less likely to develop melanoma in this population based, case-
control study, but that their overall survival was reduced. After controlling for age, sex, 
socioeconomic status, tumour location, morphology and stage, the smoking group had an 
increased risk of death from all causes as compared to the non-smoking group. However, when 
investigating melanoma-specific mortality, no association was observed.
The mechanism responsible for the observed protective association of smoking on the risk of 
developing melanoma is not yet known, but several plausible hypotheses exist. Some authors 
hypothesize that the accumulation of nicotine in cells containing melanin suppresses the 
inflammatory response to UV-B21-23. Additionally, as smoking increases elastosis, it has been 
hypothesised that elastosis formation is protective of melanoma24. Alternative explanations 
include earlier deaths in current and ex-smokers leading to survival bias, whereby those exposed 
to smoking die before being at risk of developing melanoma. 
Melanoma is not the only condition where smoking has shown to have a favourable association, 
such as in Parkinson’s disease and ulcerative colitis25,26. The protective association in Parkinson’s 
disease has been attributed to nicotine’s ability to prevent brain damage and dopamine depletion. 
The depletion of dopamine occurs in the substantia nigra, an area of the brain populated by 
melanocytes. It is therefore plausible that Parkinson’s disease and melanoma share similar 
pathogenesis27. Numerous studies have demonstrated an increased risk of melanoma in patients 
with Parkinson’s disease and vice versa28. The inverse association of smoking and the risk of 
developing ulcerative colitis is well reported in the literature, however the pathogenesis is less 
well understood29.
The relationship with smoking status has been investigated for Non Melanoma Skin Cancers 
(NMSC). In a prospective cohort study of over one million participants, current smokers were 
found to have a reduced risk of developing Basal Cell Carcinomas (BCC). Similar to our study, 
this “protective” association was not observed in ex-smokers. Squamous Cell Carcinomas (SCC) 
are conversely more common in smokers30.
The Notch pathway, which functions broadly in specifying cell fates during embryogenesis and 
adult life, has a key role in linking the control of epidermal differentiation and proliferation31. 
Aberrant Notch signalling leads to skin cancer, although with different associations with different 
skin cancer types31. For melanoma, nodular and superficial BCC, Merkel Carcinoma and SCC in 
sun protected sites increased notched signalling has an oncogenic effect. Whilst for basosquamous 
BCC and SCC on sun exposed sites increased signalling has an oncosuppressive effects. The notch 
pathway has been found to be down regulated in smokers which could provide a further 
explanation on the protective association of smoking on melanoma and nodular BCC and the 
higher risk of SCC on sun exposed sites31-34.
Whilst we observed that smokers appeared to be at reduced risk of melanoma, their overall 
survival was reduced. This finding is not surprising given the strong relationship between smoking 
and other life limiting conditions, such as the majority of cancers and cardio-respiratory disease. 
However, consistent with the potential protective influence of smoking on melanoma 
development, the risk of death from melanoma was not different between the smokers and non-
smokers after adjusting for age, sex, stage of disease, morphology, socioeconomic status and 
tumour location. This might imply that smoking does not affect the disease progression of 
melanoma. This is however, not consistent with the work of Jones et al, who identified that at 
presentation, smokers had an increased risk of lymph node metastasis35. The discrepancy may be 
explained by the fact that the above study did not control for socioeconomic status. In addition, 
Jones et al reported an association between smoking status and Breslow thickness at presentation. 
Whilst in this study we did not have data on Breslow thickness, smoking status was not associated 
with stage at presentation.
Consistent with the published literature we found that the risk of developing melanoma was 
positively associated with socioeconomic status in this study1. The underlying explanation is 
poorly understood and likely to be complex and multifactorial. Socioeconomic status is closely 
linked with lifestyle factors such as travel, sunbed use and hobbies that are also associated with 
sunlight exposure, with the literature supporting the notion that those that are more affluent have 
greater exposure to lifestyle factors that increase melanoma incidence1,8. Our study also 
demonstrated that those in the highest socioeconomic status were less likely to smoke.
Despite higher socioeconomic status being associated with an increased risk of melanoma 
development, lower socioeconomic status is associated with poorer survival once diagnosed. This 
relationship was observed in both overall and disease specific survival rates. This is consistent 
with the broader health literature where it has been shown that lower socioeconomic status is 
associated with premature mortality from a number of conditions such as cardiovascular disease, 
respiratory disease and some malignancies36. In previous studies, low socioeconomic status has 
been associated with later stage of melanoma diagnosis, however this was not observed in this 
study. Our results may be explained by the measure used to classify socioeconomic status, the 
WIMD score. One of the seven domains used to determine the WIMD quintile is health, which is 
determined by the number of limiting long-term illnesses, all cause death rate, cancer incidence 
and birth weight. Patients within the low socioeconomic status group may therefore have other 
attributable factors influencing survival.
Limitations of this study included missing data, the lack of information available on ethnicity and 
UV light exposure. As with any population-based study, missing data prevented analysis on the 
total cohort. Data were missing for some of the cohort on smoking status and stage of disease. 
Smoking status was obtained from Welsh Longitudinal General Practice (WLGP), as recorded 
during patient’s consultations with their GP. To date, the WLGP covers 80% of GP practices 
across Wales. Of the 2,512 patients for which smoking data were absent, 2,431 (96.7%) belonged 
to GP practices not contributing data to the SAIL Databank. It is therefore assumed that data for 
this variable were missing at random and would not bias the results. Additionally, information was 
not available on the quantity of tobacco smoked by participants. The Read codes listed in the 
appendix do indeed capture some information on the amount of smoking. In practice, these codes 
were rarely utilised by General Practitioners, with the majority simply recording 137R (Current 
smoker) and therefore we were unable to provide meaningful results. This is a substantial 
limitation as the cumulative exposure to tobacco was not assessed, thus it was not possible to 
calculate a dose response relationship.
When stage of melanoma was not recorded in the WCISU data and could not be obtained from 
other linked data, these data were missing. To assess the effect of this missingness, sensitivity 
analysis were performed. Missing data were incorporated into the regression model as a separate 
category for stage. This was found not to affect the statistical significances outlined in the results 
section.
A further limitation of population-based studies using routinely collected data is incomplete 
control of confounding, that of data that are not specified, incompletely captured or misclassified, 
namely tumour location (relating to ICD 10 Code C43.9 melanoma unspecified) and tumour 
morphology (M7203 - MM NOS (melanoma – not otherwise specified)). The classification codes 
used to extract smoking status from GP data have shown to classify 8.6% ex-smokers as never 
smokers. Any misclassification would not significantly bias the results.
Ethnicity is only available on special request within the SAIL Databank and was therefore not 
incorporated into the statistical model. In Wales, population statistics reveal that 95% of the 
population are white and therefore the significance of ethnicity on the results would be minimal37. 
Conclusion
This is the largest study to date indicating that smoking has an inverse relationship on the risk of 
developing melanoma. Whilst the detrimental repercussions of smoking are well documented, 
further work is required to uncover the mechanism underlying this relationship, including further 
assessment about survival bias. If a biological association seems likely, this could lead to the 
development of novel prevention and treatment options, opening up a new wave of medical 
therapy for melanoma. Furthermore, this work reinforces the ongoing association between 
melanoma and socioeconomic status. Despite numerous public health strategies, higher 
socioeconomic groups continue to have a higher incidence of melanoma, however, lower 
socioeconomic status is related to poor survival once melanoma is diagnosed. The implications of 
these results, in a country such as the United Kingdom where healthcare is free to all, are 
significant. Further work is required to investigate how barriers to care may exist for the lowest 
socioeconomic status group so that policies can be implemented to prevent healthcare inequality 
and improve melanoma outcomes for all.
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Annual District Death 
Extract (ADDE)
Collected from the Office for National Statistics (ONS), containing 
death registration information, relating to Welsh residents including 
those who died outside of Wales.
Outpatient Dataset for 
Wales (OPDW)
Administrative and clinical data obtained from outpatient 
appointments in Wales.
Patient Episode Database 
for Wales (PEDW)
Administrative and clinical data for all hospital admissions, 





The national cancer registry for Wales. Captures all welsh melanoma 
patients from a number of sources; Multi-Disciplinary Team data, 









Administrative data about individuals resident or registered in Wales 
that have used National Health Service (NHS) services.
Table 2
Parameter Cases (n=7,124) Controls (n=24,608) P-Value
Median (Interquartile 
range)
63.0 (50.0-74.0) 43.0 (26.0-60.0)
Age Group, n (%)
<20 46 (0.7) 3,980 (16.2) 0.00
20-29 262 (3.7) 3,866 (15.7)
30-39 488 (6.9) 3,898 (15.8)
40-49 833 (11.7) 4,230 (17.2)
50-59 1,312 (18.4) 3,801 (15.5)
60-69 1,582 (22.2) 3,180 (12.3)
70-79 1,654 (23.2) 2,230 (9.1)
80-89 974 (13.7) 1030 (4.2)
>90 144 (2.0) 193 (0.8)
Sex, n (%)
Male 3,489 (49.0) 12,735 (51.8) 0.26
Female 3,635 (51.0) 1,3673 (55.6)
WIMD Quintile, n (%)
1 1,010 (14.18) 5502 (22.4) 0.00
2 1,202 (16.87) 5329 (21.7)
3 1,464 (20.6) 5333 (21.7)
4 1,446 (20.3) 4797 (19.5)
5 1,996 (28.0) 5447 (22.1)
Unspecified 6 (0.1) 0 (0.0)
Smoking status
Non-Smoker 2599 (36.5) 10,128 (41.2) 0.00
Ex-Smoker 3065 (43.0) 7,326 (29.8)




(95% C.I.for Odds Ratio)
Age 0.00 1.04 (1.04 -1.05)
Non-Smokers Reference
Ex-Smokers 0.17 1.05 (0.98 - 1.12)
Smokers 0.00 0.70 (0.65 -0.76)
Male 0.26 0.97 (0.92 - 1.02)
WIMD Q1 (lowest socioeconomic status) Reference
WIMD Q2 0.09 1.09 (0.97 - 1.20)
WIMD Q3 0.00 1.20 (1.09 - 1.32)
WIMD Q4 0.00 1.30 (1.18 - 1.43)






























Age Group, n (%)
0 - 9 <5* (0.1) <5* (0.2) 0 (0) 0 (0) 0 (0)
10-19 46 (0.5) 13 (0.5) 20 (0.8) <5* (0.2) 9 (0.6)
20-29 327 (3.4) 82 (3.3) 97 (3.7) 57 (1.9) 91 (6.2)
30-39 726 (7.5) 180 (7.2) 221 (8.5) 154 (5.0) 171 (11.7)
40-49 1,242 (12.9) 291 (11.6) 406 (15.6) 266 (8.7) 279 (19.1)
50-59 1,615 (16.8) 385 (15.3) 480 (18.5) 417 (13.6) 333 (22.8)
60-69 2,103 (21.8) 536 (21.3) 552 (21.2) 716 (23.4) 299 (20.5)
70-79 2,085 (21.6) 571 (22.7) 471 (18.1) 850 (27.7) 193 (13.2)
80-89 1,257 (13.0) 368 (14.6) 294 (11.3) 515 (16.8) 80 (5.5)
90-99 230 (2.4) 82 (3.3) 57 (2.2) 86 (2.8) 5 (0.3)
>100 <5*(0.1) 0 (0) <5* (0.2) 0 (0) 0 (0)
Sex, n (%)
Male 4,750 (49.3) 1,261 (50.2) 1161 (44.7) 1661 (54.2) 667 (45.7) <0.00
Female 4,886 (50.7) 1,251 (49.8) 1438 (55.3) 1404 (45.8) 793 (54.3)
WIMD Quintile, n (%)
1 (Lowest socioeconomic status) 1,300 (13.5) 290 (11.5) 269 (10.4) 450 (14.7) 291 (19.9) <0.00
2 1,662 (17.2) 460 (18.3) 382 (14.7) 508 (16.6) 312 (21.4)
3 1,951 (20.2) 487 (19.3 507 (19.5) 669 (21.8) 288 (19.7)
4 2,169 (22.5) 723 (28.8) 558 (21.5) 606 (19.8) 282 (19.3)
5 (highest socioeconomic status) 2,547 (26.4 551 (21.9) 881 (33.9) 828 (27.0) 287 (19.7)
Unspecified 7 (0.1) 0 (0) <5* (0.1) <5* (0.2) <5*
Mean Charlson Co-morbidity 
Score




Head & Neck 1,836 (19.1) 521 (37.9) 451 (17.4) 649 (21.2) 216 (14.8) <0.00
Upper Limb 2,071 (21.5) 497 (19.8) 758 (29.2) 662 (21.6) 466 (31.9)
Lower Limb 2,370 (24.6) 593 (23.6) 593 (22.8) 685 (22.3) 319 (21.8)
Trunk 2,884 (29.9) 706 (28.1) 698 (26.9) 956 (31.2) 395 (27.1)
Unspecified 476 (4.9) 195 (9.9) 99 (3.8) 113 (2.1) 64 (4.4)
Stage, n (%)
1 4,216 (43.8) 900 (35.8) 1220 (46.9) 1484 (48.4) 612 (41.9) 0.06
2 1,837 (19.1) 488 (19.4) 473 (18.2) 676 (22.1) 200 (13.7)
3 319 (3.3) 100 (4.0) 82 (3.2) 95 (3.1) 42 (2.9)
4 125 (1.3) 30 (1.2) 39 (1.5) 35 (1.1) 21 (1.4)
Unspecified 3,139 (32.6) 994 (39.6) 785 (30.2) 775 (25.3) 585 (40.1)
Morphology, n (%)
MM NOS 3,122 (32.4) 954 (38.0) 798 (30.7) 844 (27.5) 526 (36.0) <0.00 
Superficial Spreading 
Melanoma
4,129 (42.8) 887 (35.3) 1,221 (47.0) 1,367 (44.6) 654 (44.8)
Nodular Melanoma 1,578 (16.4) 436 (17.4) 387(14.9) 561 (18.3) 194 (13.3)
MM in lentigo maligna 466 (4.8) 124 (4.9) 109 (4.2) 187 (6.1) 46 (3.2)
Other+ 347 (3.6) 111 (4.4) 84 (3.2) 106 (3.5) 40 (2.7)
* = Results under 5 are not released from SAIL via disclosure control policies, to ensure privacy protection adherence.
+ = Balloon cell melanoma, Regressing melanoma, Amelanotic melanoma, MM in junctional naevus, Acral lentigous MM,
Desmoplastic melanoma, MM in giant pigment naevus, mixed epithelial and spindle cell, Epitheliod cell, Spindle cell NOS, 














Female *  *
Male 0.00 1.28 (1.13 - 1.46) 0.01 1.35 (1.12 - 1.62)
Smoking status
Non Smoker * *
Ex-Smoker 0.93 1.00 (0.87 - 1.14) 0.20 0.88 (0.73 - 1.07)
Smoker 0.03 1.31 (1.09 - 1.55) 0.25 1.15 (0.91 - 1.45)
WIMD Quintile
1 (Lowest socioeconomic status) * *
2 0.75 0.97 (0.80 - 1.18) 0.93 0.99 (0.75 - 1.30)
3 0.01 0.78 (0.65 - 0.95) 0.09 0.79 (0.60 - 1.04)
4 0.04 0.75 (0.62 - 0.91) 0.08 0.78 (0.59 - 1.03)
5 (highest socioeconomic status) 0.00 0.67 (0.56 -0.81) 0.01 0.69 (0.53 – 0.90)
Charlson Co-morbidity Index 0.08 1.01 (1.00-1.02) 0.517 1.00 (0.99-1.02)
Location
Trunk * *
Lower Limb 0.10 0.86 (0.72 - 1.02) 0.00 0.79 (0.63 - 1.01)
Upper Limb 0.01 0.73 (0.61 - 0.88) 0.00 0.62 (0.48 - 0.79)
Head & Neck 0.48 0.94 (0.80 - 1.11) 0.06 0.80 (0.63 - 1.01)
Unspecified 0.28 1.21 (0.86 - 1.70) 0.83 1.05 (0.67 - 1.64)
Stage
1 * *
2 0.00 2.48 (2.15 - 2.86) 0.00 6.24 (4.95 - 7.88)
3 0.00 3.65 (2.96 - 4.59) 0.00 11.48 (8.52 - 15.48)
4 0.00 11.78 (8.76 - 15.53) 0.00 32.55 (22.73 - 46.61)
Age** 0.00 1.06 (1.05 - 1.06) 0.00 1.02 (1.02 - 1.03)
Morphology
Superficial Spreading Melanoma * *
Nodular Melanoma 0.96 1.15 (0.98 - 1.35) 0.08 1.23 (0.98 - 1.54)
MM in lentigo maligna 0.70 1.05 (0.81 - 1.37) 0.02 0.43 (0.21 - 0.89)
Other+ 0.12 1.25 (0.95 - 1.67) 0.50 1.16 (0.76 - 1.74)
Unspecified 0.01 1.24 (1.05 - 1.47) 0.04 1.28 (1.01 - 1.62)
* = Reference group
** = Age was included as a continuous variable in the model
Appendix
List of Read codes used for smoking status in this study.
Some codes (suffixed with %) have been presented as a set of codes under a wildcard.




1371. Never smoked tobacco N
9kn.. Non-smoker annual review - enhanced services 
administration
N
137K. Stopped smoking E
137L. Current non-smoker E
137N. Ex pipe smoker E
137O. Ex cigar smoker E
137S. Ex smoker E
137T. Date ceased smoking E
1377. Ex-trivial smoker (< 1 per day) E
1378. Ex-light smoker (1 - 9 per day) E
1379. Ex-moderate smoker (10 - 19 per day) E
137A. Ex-heavy smoker (20 - 39 per day) E
137B. Ex-very heavy smoker (40 + per day) E
137F. Ex-smoker - amount unknown E
137i. Ex tobacco chewer E
137j. Ex-cigarette smoker E
137K0 Recently stopped smoking E
9km.. Ex-smoker annual review - enhanced services 
administration
E
13p4. Smoking free weeks E
137l. Ex roll-up cigarette smoker E
745H% (Various) Smoking cessation therapy S
du3% (Various) Nicotine replacement therapy S
du6% (Various) Bupropion S
du7% (Various) additional nicotine replacement therapy S
du8% (Various) Varenicline S
du9% (Various) Nicotine withdrawal products S
E251% (Various) tobacco dependence S
137.. Tobacco consumption S
137Z Tobacco consumption NOS S
137X. Cigarette consumption S
137Y. Cigar consumption S
137E. Tobacco consumption unknown S






1372. Trivial smoker - < 1 per day S
1373. Light smoker - 1-9 per day S
1374. Moderate smoker - 10-19 per day S
1375. Heavy smoker - 20-39 per day S
1376. Very heavy smoker - 20-39 per day S
137a. Pipe tobacco consumption S
137b. Ready to stop smoking S
137C. Keeps trying to stop smoking S
137c. Thinking about stopping smoking S
137e. Smoking restarted S
137G. Trying to give up smoking S
137H. Pipe smoker S
137J. Cigar smoker S
137M. Rolls own cigarettes S
137P. Cigarette smoker S
137Q. Smoking started S
137R. Current smoker S
137V. Smoking reduced S
137D. Admitted tobacco cons untrue? S
137d. Not interested in stopping smoking S
137f. Reason for restarting smoking S
137h. Minutes from waking to first tobacco consumption S
6791. Health ed. - smoking S
67910 Health education - parental smoking S
137m. Failed attempt to stop smoking S
13p.. Smoking cessation milestones S
13p0. Negotiated date for cessation of smoking S
13p8. Lost to smoking cessation follow-up S
38DH. Fagerstrom test for nicotine dependence S
67A3. Pregnancy smoking advice S
67H1. Lifestyle advice regarding smoking S
67H6. Brief cessation for smoking cessation S
8B2B. Nicotine replacement therapy S
8B3f. Nicotine replacement therapy provided free S
8B3Y. Over the counter nicotine replacement therapy S
8BP3. Nicotine replacement therapy provided by community 
pharmacist
S
8CAg. Smoking cessation advice provided by community 
pharmacist
S
8CAL. Smoking cessation advice S
8CdB. Stop smoking service opportunity signposted S
8H7i. Referral to smoking cessation advisor S
8HBM. Stop smoking face to face follow-up S
8HkQ. Referral to NHS stop smoking service S
8HTK. Referral to stop-smoking clinic S
8I2I. Nicotine replacement therapy contraindicated S
8I2J. Bupropion contraindicated S
8I39. Nicotine replacement therapy refused S
8I3M. Bupropion refused S
8I6H. Smoking review not indicated S
8IAj. Smoking cessation advice declined S
8IEK. Smoking cessation program declined S
8IEM. Smoking cessation drug therapy declined S
9hG.. Exception reporting: smoking quality indicators S
9hG0. Excepted from smoking quality indicators: Patient 
unsuitable
S
9hG1. Excepted from smoking quality indicators: Informed 
dissent
S
9kc.. Smoking cessation - enhanced services administration S
9kc0. Smoking cessatn monitor template complet - enhanc 
serv admin
S
9ko.. Current smoker annual review - enhanced service 
admin
S
9N2k. Seen by smoking cessation advisor S
9N4M. DNA - did not attend smoking cessation clinic S
9Ndg. Declined consent for follow-up by smoking cessation 
team
S
9NdV. Consent given follow-up after smoking cessation 
intervention
S
9NdW. Consent given for smoking cessation data sharing S
9NdY. Declin cons follow-up evaluation after smoking cess 
interven
S
9NdZ. Declined consent for smoking cessation data sharing S
9NS02 Referral for smoking cessation service offered S
9OO.. Attends stop smoking monitor admin S
9OO1. Attends stop smoking monitor S
9OO2. Refuses stop smoking monitor S
9OO3. Stop smoking monitor default S
9OO4. Stop smoking monitor 1st lettr S
9OO5. Stop smoking monitor 2nd lettr S
9OO6. Stop smoking monitor 3rd lettr S
9OO7. Stop smoking monitor verb.inv. S
9OO8. Stop smoking monitor phone inv S
9OO9. Stop smoking monitoring delete S
9OOA. Stop smoking monitor check.done S
9OOB. Stop smoking invitation short message service text 
message
S
9OOB0 Stop smoking invitation first SMS text message S
9OOB1 Stop smoking invitation second SMS text message S
9OOB2 Stop smoking invitation third SMS text message S
9OOZ. Stop smoking monitor admin.NOS S
E023. Nicotine withdrawal S
J0364 Tobacco deposit on teeth S
SMC. Toxic effect of tobacco and nicotine S
TJHy2 Adverse reaction to nicotine S
U6099 [X] Bupropion causing adverse effects in therapeutic
use
S
ZV4K0 [V] Tobacco use S
ZV6D8 [V] Tobacco abuse counselling S
13p5. Smoking cessation programme start date S




The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using 
routinely collected health data.
Item 
No.
STROBE items Location in 
manuscript where 
items are reported
RECORD items Location in 
manuscript 
where items are 
reported
Title and abstract
1 (a) Indicate the study’s design
with a commonly used term in 
the title or the abstract (b) 
Provide in the abstract an 
informative and balanced 
summary of what was done and 
what was found
RECORD 1.1: The type of data used 
should be specified in the title or 
abstract. When possible, the name of 
the databases used should be included.
RECORD 1.2: If applicable, the 
geographic region and timeframe within 
which the study took place should be 
reported in the title or abstract.
Abstract
Abstract
RECORD 1.3: If linkage between 
databases was conducted for the study, 





2 Explain the scientific background 
and rationale for the investigation 
being reported
Background
Objectives 3 State specific objectives, 




Study Design 4 Present key elements of study 
design early in the paper
Methods
Setting 5 Describe the setting, locations, 
and relevant dates, including 
periods of recruitment, exposure, 
follow-up, and data collection
Methods
Participants 6 (a) Cohort study - Give the
eligibility criteria, and the 
sources and methods of selection 
of participants. Describe methods 
of follow-up
Case-control study - Give the 
eligibility criteria, and the 
sources and methods of case 
ascertainment and control 
selection. Give the rationale for 
the choice of cases and controls
Cross-sectional study - Give the 
eligibility criteria, and the 
sources and methods of selection 
of participants
(b) Cohort study - For matched
studies, give matching criteria 
and number of exposed and 
unexposed
RECORD 6.1: The methods of study 
population selection (such as codes or 
algorithms used to identify subjects) 
should be listed in detail. If this is not 
possible, an explanation should be 
provided. 
RECORD 6.2: Any validation studies of 
the codes or algorithms used to select 
the population should be referenced. If 
validation was conducted for this study 
and not published elsewhere, detailed 
methods and results should be provided.
RECORD 6.3: If the study involved 
linkage of databases, consider use of a 
flow diagram or other graphical display 
to demonstrate the data linkage process, 
including the number of individuals 




Case-control study - For matched 
studies, give matching criteria 
and the number of controls per 
case
Variables 7 Clearly define all outcomes, 
exposures, predictors, potential 
confounders, and effect 
modifiers. Give diagnostic 
criteria, if applicable.
RECORD 7.1: A complete list of codes 
and algorithms used to classify 
exposures, outcomes, confounders, and 
effect modifiers should be provided. If 





8 For each variable of interest, give 
sources of data and details of 
methods of assessment 
(measurement).
Describe comparability of 
assessment methods if there is 
more than one group
Methods
Bias 9 Describe any efforts to address 
potential sources of bias
Methods





11 Explain how quantitative 
variables were handled in the 
analyses. If applicable, describe 





12 (a) Describe all statistical
methods, including those used to 
control for confounding
(b) Describe any methods used to
examine subgroups and 
interactions
(c) Explain how missing data
were addressed
(d) Cohort study - If applicable,
explain how loss to follow-up 
was addressed
Case-control study - If 
Methods
applicable, explain how matching 
of cases and controls was 
addressed
Cross-sectional study - If 
applicable, describe analytical 
methods taking account of 
sampling strategy
(e) Describe any sensitivity
analyses
Methods
Data access and 
cleaning methods
.. RECORD 12.1: Authors should 
describe the extent to which the 
investigators had access to the database 
population used to create the study 
population.
RECORD 12.2: Authors should provide 
information on the data cleaning 
methods used in the study.
Methods
Linkage .. RECORD 12.3: State whether the study Methods
included person-level, institutional-
level, or other data linkage across two 
or more databases. The methods of 
linkage and methods of linkage quality 
evaluation should be provided.
Results
Participants 13 (a) Report the numbers of
individuals at each stage of the 
study (e.g., numbers potentially 
eligible, examined for eligibility, 
confirmed eligible, included in 
the study, completing follow-up, 
and analysed)
(b) Give reasons for non-
participation at each stage.
(c) Consider use of a flow
diagram
RECORD 13.1: Describe in detail the 
selection of the persons included in the 
study (i.e., study population selection) 
including filtering based on data 
quality, data availability and linkage. 
The selection of included persons can 
be described in the text and/or by means 
of the study flow diagram.
Results
Descriptive data 14 (a) Give characteristics of study
participants (e.g., demographic, 
Results
clinical, social) and information 
on exposures and potential 
confounders
(b) Indicate the number of
participants with missing data for 
each variable of interest
(c) Cohort study - summarise
follow-up time (e.g., average and 
total amount)
Outcome data 15 Cohort study - Report numbers of 
outcome events or summary 
measures over time
Case-control study - Report 
numbers in each exposure 
category, or summary measures 
of exposure
Cross-sectional study - Report 
numbers of outcome events or 
summary measures
Results
Main results 16 (a) Give unadjusted estimates
and, if applicable, confounder-
adjusted estimates and their 
precision (e.g., 95% confidence 
interval). Make clear which 
confounders were adjusted for 
and why they were included
(b) Report category boundaries
when continuous variables were 
categorized
(c) If relevant, consider
translating estimates of relative 
risk into absolute risk for a 
meaningful time period
Results
Other analyses 17 Report other analyses done—e.g., 
analyses of subgroups and 




Key results 18 Summarise key results with 
reference to study objectives
Discussion
Limitations 19 Discuss limitations of the study, 
taking into account sources of 
potential bias or imprecision. 
Discuss both direction and 
magnitude of any potential bias
RECORD 19.1: Discuss the 
implications of using data that were not 
created or collected to answer the 
specific research question(s). Include 
discussion of misclassification bias, 
unmeasured confounding, missing data, 
and changing eligibility over time, as 
they pertain to the study being reported.
Discussion
Interpretation 20 Give a cautious overall 
interpretation of results 
considering objectives, 
limitations, multiplicity of 
analyses, results from similar 
studies, and other relevant 
evidence
Discussion
Generalisability 21 Discuss the generalisability 




Funding 22 Give the source of funding and 
the role of the funders for the 
present study and, if applicable, 
for the original study on which 






.. RECORD 22.1: Authors should provide 
information on how to access any 
supplemental information such as the 
study protocol, raw data, or 
programming code.
Discussion
Table 6 Overall and disease specific survival rates by smoking status
Table 7  Overall and disease specific survival rates by socioeconomic status.

















WIMD Quintile 1 (Lowest 
socioeconomic status)
90.5 68.3 56.1 93.2 78.3 73.9
WIMD Quintile 2 90.6 70 58.6 94.1 81.3 76.9
WIMD Quintile 3 91.1 73.2 62.9 94.2 83.3 78.3
WIMD Quintile 4 92.2 74.6 64.2 94.2 83.7 79.9
WIMD Quintile 5 (highest 
socioeconomic status)
93.4 77.2 66.6 95.5 85 81.1













Non Smoker 94.1 79.8 70.5 95.6 86.3 85.9
Ex-Smoker 93.7 75.3 61.7 96.3 86.5 82.5
Current 
Smoker
95.5 80.7 70.7 96.4 86.9 82.9
